Press release Biocartis NV: Biocartis appoints renowned precision oncology expert, Dr. W. Michael Korn, as Chief Medical and Scientific Officer
13 Agosto 2024 - 9:00AM
PRESS RELEASE - 13/08/2024, 16:00 CEST
Biocartis appoints renowned precision
oncology expert, Dr. W. Michael Korn, as
Chief Medical and Scientific Officer
Mechelen, Belgium, 13 August 2024
– Biocartis NV (“Biocartis”), an innovative molecular diagnostics
company, is pleased to announce the appointment of Dr. W. Michael
Korn as its Chief Medical and Scientific Officer effective 12
August 2024.
Before joining Biocartis, Dr. Korn served as Chief
Medical Officer at Invitae Corporation where he focused on
broadening the indications for genetic testing and led the
development of novel clinical studies of an advanced MRD assay. Dr.
Korn also served as Chief Medical Officer at Caris Life Sciences
where he was instrumental in developing AI-driven molecular
signatures and advancing clinical and translational research in
precision oncology. Dr. Korn is a faculty member (volunteer) at
the University of California San Francisco (UCSF) in the
Division of Hematology/Oncology. He co-founded the Center for
Molecular Oncology Initiative at the UCSF Helen Diller Family
Comprehensive Cancer Center.
“The ever-growing number of molecularly-informed
treatments in oncology requires access to fast, accurate, and
high-quality molecular information to allow for expeditious and
personalized treatment decisions for patients diagnosed with
cancer,” said Dr. Korn.
“Biocartis’ decentralized approach fulfills this need by delivering
critically important molecular test results at the point of care in
a timeframe that is measured in hours. I look forward to working
with the Biocartis team on providing rapid, clinically-relevant
molecular testing to patients with cancer worldwide.”
Dr. Korn earned his medical doctorate at the
Philipps University Marburg and graduated from the Heinrich Heine
University of Düsseldorf in Germany. He completed his internal
medicine and medical oncology training at the West German Cancer
Center in Essen, Germany. He is board certified in internal
medicine and medical oncology.
“We are delighted to have Dr. Michael Korn join
Biocartis as our new Chief Medical and Scientific Officer. His
extensive expertise in oncology diagnostics will be crucial in our
efforts to deliver rapid and actionable molecular diagnostics to
improve cancer care,” stated Roger Moody,
Chief Executive Officer of Biocartis.
----- END -----
More information:
www.biocartis.com
info@biocartis.com
About Biocartis
With its revolutionary and proprietary Idylla™
Platform, Biocartis aspires to enable personalized medicine for
patients around the world through universal access to molecular
testing, by making molecular testing actionable, convenient, fast
and suitable for any lab. The Idylla™ Platform is a fully automated
sample-to-result, real-time PCR (Polymerase Chain Reaction) based
system designed to offer in-house access to accurate molecular
information in a minimum amount of time for faster, informed
treatment decisions. Idylla™'s continuously expanding menu of
molecular diagnostic tests addresses key unmet clinical needs, with
a focus in oncology. This is the fastest growing segment of the
molecular diagnostics market worldwide. Today, Biocartis offers
tests supporting melanoma, colorectal, lung, breast, thyroid,
brain, blood and liver cancer. More
information: www.biocartis.com. Follow us on X (Twitter):
@Biocartis.
Biocartis and Idylla™ are registered trademarks in
Europe, the United States and other countries. The Biocartis and
Idylla™ trademark and logo are used trademarks owned by Biocartis.
Please refer to the product labeling for applicable intended uses
for each individual Biocartis product. © August 2024,
Biocartis NV. All rights reserved.